Search results for "F-18-FDG PET"

showing 2 items of 2 documents

Metabolic Response Assessment in Non-Small Cell Lung Cancer Patients after Platinum-Based Therapy: A Preliminary Analysis

2015

The purpose of this study was to evaluate the clinical value of PET (Positron Emission Tomography) for early prediction of tumor response to platinum-based therapy in patients with nonsmall cell lung cancer (NSCLC). The evaluation was carried out comparing the standard treatment response using RECIST (Response Evaluation Criteria in Solid Tumors) with metabolic treatment response according to European Organization for Research and Treatment of Cancer (EORTC) recommendations, PET Response Criteria in Solid Tumors (PERCIST), Total Lesion Glycolysis (TLG) and Metabolic Tumor Volume (MTV). Seventeen inoperable patients with stage IV NSCLC were enrolled between October 2011 and June 2013: PET st…

Oncologymedicine.medical_specialtybusiness.industryF-FDG PETmedicine.disease18 F-FDG PET EORTC Non-small cell lung cancer PERCIST RECIST Therapy MonitoringPreliminary analysisResponse assessmentEORTCNon-small cell lung cancerRECISTTherapy MonitoringInternal medicinemedicineF-18-FDG PETRadiology Nuclear Medicine and imagingTherapy monitoringRadiologyNon small cellLung cancerbusinessPERCIST
researchProduct

Multiparametric 18F-FDG PET-MRI of the breast: are there differences in imaging biomarkers of contralateral healthy tissue between patients with and …

2019

The rationale was to assess whether there are differences in multiparametric 18F-FDG PET/MRI biomarkers of contralateral healthy breast tissue in patients with benign and malignant breast tumors. Methods: In this institutional review board-approved prospective single-institution study, 141 women with imaging abnormalities on mammography or sonography (BI-RADS 4/5) underwent combined 18F-FDG PET/MRI of the breast at 3T with dynamic contrast-enhanced MRI, diffusion-weighted imaging, and the radiotracer 18F-FDG. In all patients, the following imaging biomarkers were recorded for the contralateral (tumor-free) breast: breast parenchymal uptake (BPU) (from 18F-FDG PET), mean apparent diffusion c…

medicine.medical_specialtyImaging biomarkerdiffusion-weighted imagingMalignancy030218 nuclear medicine & medical imaging03 medical and health sciences0302 clinical medicineBreast cancerbreast cancerF-18-FDG PET/MRImedicineMammographyEffective diffusion coefficientF-18-FDG PET/MRI breast cancer; dynamic contrast-enhanced MRI diffusion-weighted imaging imaging biomarkerimaging biomarkerRadiology Nuclear Medicine and imagingdynamic contrast-enhanced MRImedicine.diagnostic_testbusiness.industryCancermedicine.disease030220 oncology & carcinogenesisDynamic contrast-enhanced MRIRadiologybusinessDiffusion MRI
researchProduct